Emerging Targets of Diuretic Therapy

C. J. Cheng, A. R. Rodan, C. L. Huang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Diuretics are commonly prescribed for treatment in patients with hypertension, edema, or heart failure. Studies on hypertensive and salt-losing disorders and on urea transporters have contributed to better understanding of mechanisms of renal salt and water reabsorption and their regulation. Proteins involved in the regulatory pathways are emerging targets for diuretic and aquaretic therapy. Integrative high-throughput screening, protein structure analysis, and chemical modification have identified promising agents for preclinical testing in animals. These include WNK-SPAK inhibitors, ClC-K channel antagonists, ROMK channel antagonists, and pendrin and urea transporter inhibitors. We discuss the potential advantages and side effects of these potential diuretics.

Original languageEnglish (US)
Pages (from-to)420-435
Number of pages16
JournalClinical Pharmacology and Therapeutics
Volume102
Issue number3
DOIs
StatePublished - Sep 1 2017

Fingerprint

Diuretics
Salts
Edema
Proteins
Therapeutics
Heart Failure
Hypertension
Kidney
Water
urea transporter

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging Targets of Diuretic Therapy. / Cheng, C. J.; Rodan, A. R.; Huang, C. L.

In: Clinical Pharmacology and Therapeutics, Vol. 102, No. 3, 01.09.2017, p. 420-435.

Research output: Contribution to journalArticle

@article{8389d96c6fff422fb6ec30200e8508ed,
title = "Emerging Targets of Diuretic Therapy",
abstract = "Diuretics are commonly prescribed for treatment in patients with hypertension, edema, or heart failure. Studies on hypertensive and salt-losing disorders and on urea transporters have contributed to better understanding of mechanisms of renal salt and water reabsorption and their regulation. Proteins involved in the regulatory pathways are emerging targets for diuretic and aquaretic therapy. Integrative high-throughput screening, protein structure analysis, and chemical modification have identified promising agents for preclinical testing in animals. These include WNK-SPAK inhibitors, ClC-K channel antagonists, ROMK channel antagonists, and pendrin and urea transporter inhibitors. We discuss the potential advantages and side effects of these potential diuretics.",
author = "Cheng, {C. J.} and Rodan, {A. R.} and Huang, {C. L.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1002/cpt.754",
language = "English (US)",
volume = "102",
pages = "420--435",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Emerging Targets of Diuretic Therapy

AU - Cheng, C. J.

AU - Rodan, A. R.

AU - Huang, C. L.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Diuretics are commonly prescribed for treatment in patients with hypertension, edema, or heart failure. Studies on hypertensive and salt-losing disorders and on urea transporters have contributed to better understanding of mechanisms of renal salt and water reabsorption and their regulation. Proteins involved in the regulatory pathways are emerging targets for diuretic and aquaretic therapy. Integrative high-throughput screening, protein structure analysis, and chemical modification have identified promising agents for preclinical testing in animals. These include WNK-SPAK inhibitors, ClC-K channel antagonists, ROMK channel antagonists, and pendrin and urea transporter inhibitors. We discuss the potential advantages and side effects of these potential diuretics.

AB - Diuretics are commonly prescribed for treatment in patients with hypertension, edema, or heart failure. Studies on hypertensive and salt-losing disorders and on urea transporters have contributed to better understanding of mechanisms of renal salt and water reabsorption and their regulation. Proteins involved in the regulatory pathways are emerging targets for diuretic and aquaretic therapy. Integrative high-throughput screening, protein structure analysis, and chemical modification have identified promising agents for preclinical testing in animals. These include WNK-SPAK inhibitors, ClC-K channel antagonists, ROMK channel antagonists, and pendrin and urea transporter inhibitors. We discuss the potential advantages and side effects of these potential diuretics.

UR - http://www.scopus.com/inward/record.url?scp=85022189259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022189259&partnerID=8YFLogxK

U2 - 10.1002/cpt.754

DO - 10.1002/cpt.754

M3 - Article

C2 - 28560800

AN - SCOPUS:85022189259

VL - 102

SP - 420

EP - 435

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -